News | May 30, 2023
Jubilant Pharmova posts Q4FY23 consolidated loss at Rs. 97.84 Cr
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 3276.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 880.59 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
